



CORRESPONDENCE

Reply to ‘Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses’

British Journal of Cancer (2018) 118:1154; <https://doi.org/10.1038/s41416-018-0032-y>

We thank Sauerbrei and Haeussler¹ for their interest in our paper² and their methodological comments. Our aim was to undertake these analyses and draw some conclusions from the available literature regarding the prognostic significance of BAG-1 in breast cancer, given multiple studies. We felt that this was important, particularly since BAG-1 is already included in multi-gene assays widely used as part of routine clinical practice and due to ongoing investigation into the possibility of inhibition of BAG-1 function as a potential therapeutic strategy. We did not use the supplementary information provided within the REMARK Explanation and Elaboration paper.³ We provided our interpretation whether details within the REMARK checklist were included in the papers and, as we highlighted, the literature reviewed was heterogeneous and with a range in study quality. We believe our conclusions were drawn with appropriate caveats to highlight this.

ADDITIONAL INFORMATION

Competing interests: The authors declare no competing interests.

Note: This work is published under the standard license to publish agreement. After 12 months, the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

E. S. Papadakis¹, T. Reeves¹, N. H. Robson¹, T. Maishman²,
G. Packham¹ and R. I. Cutress^{1,3}

¹*Cancer Research UK Centre Cancer Sciences Unit, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK;*
²*Southampton Clinical Trials Unit, University of Southampton, Southampton SO17 1BJ, UK and* ³*University Hospital Southampton, University of Southampton Faculty of Medicine, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK*
Correspondence: T Reeves (T.Reeves@soton.ac.uk)

REFERENCES

1. Sauerbrei W, Haeussler T. Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses’. *Br. J. Cancer* <https://doi.org/10.1038/s41416-018-0023-z> (2018).
2. Papadakis, E. S. et al. BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. *Br. J. Cancer* **116**, 1585–1594, <https://doi.org/10.1038/bjc.2017.130> (2017).
3. Altman, D. G., McShane, L. M., Sauerbrei, W. & Taube, S. E. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. *BMC Med.* **10**, 51 (2012).